vs
Side-by-side financial comparison of bioAffinity Technologies, Inc. (BIAF) and Peraso Inc. (PRSO). Click either name above to swap in a different company.
Peraso Inc. is the larger business by last-quarter revenue ($2.9M vs $1.6M, roughly 1.8× bioAffinity Technologies, Inc.). Peraso Inc. runs the higher net margin — -43.3% vs -197.0%, a 153.7% gap on every dollar of revenue. On growth, Peraso Inc. posted the faster year-over-year revenue change (-22.0% vs -27.8%). Over the past eight quarters, Peraso Inc.'s revenue compounded faster (1.0% CAGR vs -18.6%).
bioAffinity Technologies, Inc. is a clinical-stage biotechnology firm focused on developing non-invasive in vitro diagnostic tests for early detection of cancer and respiratory diseases. It serves global healthcare markets, with a core mission to deliver accessible, high-accuracy diagnostic solutions that improve patient outcomes and reduce overall healthcare system costs.
Peraso Inc. is a semiconductor technology firm specializing in the design and production of high-performance millimeter wave (mmWave) integrated circuits and modules. It delivers 5G and next-generation wireless connectivity solutions for telecom infrastructure, industrial IoT, fixed wireless access and consumer electronics segments, serving customers across North America, Asia Pacific and European markets.
BIAF vs PRSO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $2.9M |
| Net Profit | $-3.1M | $-1.2M |
| Gross Margin | — | 52.2% |
| Operating Margin | -196.9% | -44.6% |
| Net Margin | -197.0% | -43.3% |
| Revenue YoY | -27.8% | -22.0% |
| Net Profit YoY | -5.7% | 20.3% |
| EPS (diluted) | $-3.59 | $-0.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $2.9M | ||
| Q3 25 | $1.4M | $3.2M | ||
| Q2 25 | $1.3M | $2.2M | ||
| Q1 25 | $1.9M | $3.9M | ||
| Q4 24 | $2.2M | $3.7M | ||
| Q3 24 | $2.4M | $3.8M | ||
| Q2 24 | $2.4M | $4.2M | ||
| Q1 24 | $2.4M | $2.8M |
| Q4 25 | $-3.1M | $-1.2M | ||
| Q3 25 | $-5.1M | $-1.2M | ||
| Q2 25 | $-4.1M | $-1.8M | ||
| Q1 25 | $-2.7M | $-471.0K | ||
| Q4 24 | $-3.0M | $-1.6M | ||
| Q3 24 | $-2.0M | $-2.7M | ||
| Q2 24 | $-2.1M | $-4.4M | ||
| Q1 24 | $-2.0M | $-2.0M |
| Q4 25 | — | 52.2% | ||
| Q3 25 | — | 56.2% | ||
| Q2 25 | — | 48.3% | ||
| Q1 25 | — | 69.3% | ||
| Q4 24 | — | 56.3% | ||
| Q3 24 | — | 47.0% | ||
| Q2 24 | — | 55.5% | ||
| Q1 24 | — | 46.4% |
| Q4 25 | -196.9% | -44.6% | ||
| Q3 25 | -158.6% | -36.8% | ||
| Q2 25 | -198.2% | -80.0% | ||
| Q1 25 | -141.7% | -13.3% | ||
| Q4 24 | -133.5% | -44.3% | ||
| Q3 24 | -84.0% | -70.3% | ||
| Q2 24 | -87.1% | -105.6% | ||
| Q1 24 | -80.8% | -128.9% |
| Q4 25 | -197.0% | -43.3% | ||
| Q3 25 | -349.3% | -37.4% | ||
| Q2 25 | -319.9% | -82.4% | ||
| Q1 25 | -143.5% | -12.2% | ||
| Q4 24 | -134.4% | -42.4% | ||
| Q3 24 | -85.1% | -70.6% | ||
| Q2 24 | -88.0% | -104.4% | ||
| Q1 24 | -81.5% | -72.1% |
| Q4 25 | $-3.59 | $-0.09 | ||
| Q3 25 | $-4.74 | $-0.17 | ||
| Q2 25 | $-0.17 | $-0.31 | ||
| Q1 25 | $-0.16 | $-0.10 | ||
| Q4 24 | $-17.27 | $0.36 | ||
| Q3 24 | $-4.84 | $-0.98 | ||
| Q2 24 | $-0.19 | $-1.88 | ||
| Q1 24 | $-0.20 | $-1.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.4M | $2.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.3M | $4.6M |
| Total Assets | $11.0M | $6.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.4M | $2.9M | ||
| Q3 25 | $7.7M | — | ||
| Q2 25 | $802.8K | — | ||
| Q1 25 | $444.7K | — | ||
| Q4 24 | $1.1M | $3.3M | ||
| Q3 24 | $756.6K | $1.3M | ||
| Q2 24 | $801.3K | $1.9M | ||
| Q1 24 | $2.5M | $2.4M |
| Q4 25 | $7.3M | $4.6M | ||
| Q3 25 | $8.9M | $3.6M | ||
| Q2 25 | $-2.1M | $3.0M | ||
| Q1 25 | $1.4M | $3.6M | ||
| Q4 24 | $2.6M | $3.5M | ||
| Q3 24 | $3.1M | $2.0M | ||
| Q2 24 | $3.4M | $3.6M | ||
| Q1 24 | $5.3M | $6.7M |
| Q4 25 | $11.0M | $6.1M | ||
| Q3 25 | $11.5M | $6.2M | ||
| Q2 25 | $4.8M | $5.5M | ||
| Q1 25 | $5.5M | $6.7M | ||
| Q4 24 | $6.5M | $7.2M | ||
| Q3 24 | $6.6M | $7.2M | ||
| Q2 24 | $6.7M | $9.8M | ||
| Q1 24 | $8.0M | $11.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.6M | $-1.1M |
| Free Cash FlowOCF − Capex | $-2.6M | — |
| FCF MarginFCF / Revenue | -160.7% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-9.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.6M | $-1.1M | ||
| Q3 25 | $-2.5M | $-1.5M | ||
| Q2 25 | $-2.6M | $-2.0M | ||
| Q1 25 | $-1.6M | $-966.0K | ||
| Q4 24 | $-1.7M | $-687.0K | ||
| Q3 24 | $-1.7M | $-683.0K | ||
| Q2 24 | $-1.5M | $-659.0K | ||
| Q1 24 | $-2.3M | $-2.5M |
| Q4 25 | $-2.6M | — | ||
| Q3 25 | $-2.5M | $-1.6M | ||
| Q2 25 | $-2.7M | — | ||
| Q1 25 | $-1.7M | — | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-1.7M | — | ||
| Q2 24 | $-1.6M | — | ||
| Q1 24 | $-2.4M | — |
| Q4 25 | -160.7% | — | ||
| Q3 25 | -171.8% | -48.9% | ||
| Q2 25 | -209.6% | — | ||
| Q1 25 | -91.3% | — | ||
| Q4 24 | -76.0% | — | ||
| Q3 24 | -73.1% | — | ||
| Q2 24 | -65.1% | — | ||
| Q1 24 | -99.2% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.3% | 1.1% | ||
| Q2 25 | 1.1% | — | ||
| Q1 25 | 2.7% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.4% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | 1.7% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BIAF
Segment breakdown not available.
PRSO
| Products | $2.8M | 96% |
| Other | $105.0K | 4% |
